Clinical deterioration in established heart failure: What is the value of BNP and weight gain in aiding diagnosis?
暂无分享,去创建一个
C. O’loughlin | K. McDonald | M. Ledwidge | Jennifer Lewin | Mark Ledwidge | Christina O'Loughlin | Clare McNally | Ken McDonald | C. Mcnally | J. Lewin
[1] Alan S Maisel,et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.
[2] A. Ferreira,et al. N-Terminal–Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in Heart Failure Patients , 2004, Circulation.
[3] M. Kinoshita,et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. , 1999, European heart journal.
[4] K. Swedberg,et al. Guidelines for the diagnosis and treatment of chronic heart failure. , 2001, European heart journal.
[5] H. Tunstall-Pedoe,et al. Biochemical detection of left-ventricular systolic dysfunction , 1998, The Lancet.
[6] M. Drazner,et al. B-type natriuretic peptide in cardiovascular disease , 2003, The Lancet.
[7] Abdissa Negassa,et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study , 2003, The Lancet.
[8] C. Frampton,et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.
[9] J. Cahill,et al. Elimination of early rehospitalization in a randomized, controlled trial of multidisciplinary care in a high‐risk, elderly heart failure population: the potential contributions of specialist care, clinical stability and optimal angiotensin‐converting enzyme inhibitor dose at discharge , 2001, European journal of heart failure.
[10] M. Redfield,et al. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. , 2002, Journal of cardiac failure.
[11] L. Lenert,et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. , 2001, Journal of the American College of Cardiology.
[12] A. Wu,et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. , 2003, The American journal of cardiology.
[13] K. Kugiyama,et al. Localization and Mechanism of Secretion of B‐Type Natriuretic Peptide in Comparison With Those of A‐Type Natriuretic Peptide in Normal Subjects and Patients With Heart Failure , 1994, Circulation.
[14] J. Cahill,et al. Heart failure management: multidisciplinary care has intrinsic benefit above the optimization of medical care. , 2002, Journal of cardiac failure.
[15] J. Marving,et al. Symptoms and signs of heart failure in patients with myocardial infarction: reproducibility and relationship to chest X-ray, radionuclide ventriculography and right heart catheterization. , 1989, European heart journal.
[16] L. Morrison,et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea ☆ , 2002 .
[17] T. McDonagh,et al. NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. , 2003, European journal of heart failure.
[18] A. Richards,et al. Clearance receptors and endopeptidase: equal role in natriuretic peptide metabolism in heart failure. , 1997, American journal of physiology. Heart and circulatory physiology.
[19] Andrew K. Smith,et al. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure , 2004, European journal of heart failure.